A drug discovered and advanced by The University of Texas MD Anderson Cancer Center's Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells' growth and survival.
IACS-10759 is the first small molecule drug to be developed from concept to clinical trial by MD Anderson's Therapeutics Discovery team, which includes IACS and the CCCT.
Therapeutics Discovery is a unique group of clinicians, researchers and drug development experts working collaboratively to create new treatment options, including small molecules, biologics, and cell-based therapies.
New data related to IACS-10759 were published in two papers in Nature Medicine.
The first paper reports the preclinical work led by Joseph Marszalek, Ph.D., head of Translational Biology for CCCT, and Emilia Di Francesco, Ph.D., associate director of Medicinal Chemistry at IACS, which resulted in the discovery of IACS-10759 and its advancement into Phase I clinical trials for acute myeloid leukaemia (AML) and solid tumours.
A second paper, authored by Andrew Futreal, Ph.D., chair, and Yonathan Lissanu Deribe, Ph.D., instructor, both of Genomic Medicine, describes the potential of IACS-10759 for treatment of lung cancers harbouring a specific epigenetic alteration.
Metabolic reprogramming is an emerging hallmark of tumour biology where cancer cells evolve to rely on two key metabolic processes, glycolysis and oxidative phosphorylation (OXPHOS), to support their growth and survival.
Extensive efforts have focused on therapeutic targeting of glycolysis, while OXPHOS has remained largely unexplored, partly due to an incomplete understanding of tumour contexts where OXPHOS is essential.
"Through a comprehensive translational effort enabled by collaboration across MD Anderson, we have identified multiple cancers that are highly dependent on OXPHOS," said Marszalek.
This effort inspired the discovery and development of IACS-10759, a potent and selective inhibitor of OXPHOS.
Its advancement to clinical trials was made possible by a multidisciplinary team of more than 25 scientists across Therapeutics Discovery.
"Through this collaborative, 18-month process, we identified and rapidly advanced IACS-10759 as the molecule for clinical development," said Di Francesco. "We believe IACS-10759 will provide a promising new therapy for cancer patients."
The pre-clinical research conducted by IACS and CCCT led to an ongoing first-in-human Phase I clinical trial, launched in October 2016, evaluating IACS-10759 in AML, led by Marina Konopleva, M.D., Ph.D., professor, and Naval Daver, M.D., associate professor, both of Leukaemia.
Asecond Phase I trial in solid tumour indications, started in November 2017, is led by Timothy Yap, M.D., Ph.D., associate professor of Investigational Cancer Therapeutics.
IACS-10759 was evaluated in pre-clinical studies for treating lung cancers harboring mutations in the SMARCA4 gene, which render tumors sensitive to the drug due to an increased dependence on OXPHOS for survival.
SMARCA4 is a component of a chromatin modelling complex called SWI/SNF, which plays a vital role in gene expression.
The study team's analyses showed SMARCA4 mutant cells have enhanced oxygen consumption and increased respiratory capacity, making them susceptible to treatment with an OXPHOS inhibitor like IACS-10759.
"Our findings provide the mechanistic basis for further development of OXPHOS inhibitors as therapeutics against cancers with SWI/SNF-mutant tumours," said Lissanu Deribe. "Through multidisciplinary studies of new agents like IACS-10759, we aim to accelerate the availability of enhanced therapies for our patients."